Such studies will help further validate the robustness of clinical utilities of CTCs and CTECs, and unravel essential insights regarding how aneuploid CTCs and CTECs interplay in tumorigenesis, tumor neovascularization, cancer metastasis, and response to anti‐angiogenesis in combination with chemotherapy, tyrosine kinase inhibitors including erlotinib targeting the EGFR‐L858R activating mutation [58, 59], and the novel third‐generation TKI osimertinib (Tagrisso®) targeting the EGFR‐T790M resistance mutation [60], as well as immune checkpoint blockade immunotherapy [17, 61]. This evidence concerns the gene EGFR and neoplasm.